Limits...
Short-term efficacy of recombinant human GH therapy in cured acromegaly patients with GH deficiency: a single-center experience.

Dutta P, Mahendran B, Reddy KS, Ahluwalia J, Vaiphei K, Kochhar RK, Gupta P, Srinivasan A, Prakash M, Mukherjee KK, Shah VN, Parthan G, Bhansali A - Endocr Connect (2015)

Bottom Line: There was improvement in bone mineral content (P=0.01), bone mineral density (P=0.04), muscle strength (P<0.001), total cholesterol (P=0.003), high-density cholesterol (P<0.001), and QoL - score (P=0.005), and reduction in low-density cholesterol (P=0.003) and triglyceride (P=0.004) after treatment.There was a modest increase in plasminogen activator inhibitor 1 (P=0.002), but it was lower compared with healthy controls and treatment naïve acromegalics (P=0.007).Long-term prospective studies are needed to evaluate the effect of r-hGH therapy in these patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Endocrinology4th Floor, F Block, Post Graduate Institute of Medical Education and Research, Nehru Hospital, Chandigarh 160012, IndiaInternal MedicineCardiologyHematologyHistopathologyGastroenterologyNeurosurgeryPharmacologyRadiodiagnosisPost Graduate Institute of Medical Education and Research, Chandigarh 160012, India pinaki_dutta@hotmail.com.

No MeSH data available.


Related in: MedlinePlus

Bar diagram showing the median QLS-H score between the groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4321405&req=5

fig3: Bar diagram showing the median QLS-H score between the groups.

Mentions: The median (IQR) QOL score in the control group was 153 (143–149). The median (IQR) QoL in the test group before treatment was 45 (36–55.25) which improved to 84.5 (79–100) post treatment (P=0.005, Fig. 3) (Supplementary File 2).


Short-term efficacy of recombinant human GH therapy in cured acromegaly patients with GH deficiency: a single-center experience.

Dutta P, Mahendran B, Reddy KS, Ahluwalia J, Vaiphei K, Kochhar RK, Gupta P, Srinivasan A, Prakash M, Mukherjee KK, Shah VN, Parthan G, Bhansali A - Endocr Connect (2015)

Bar diagram showing the median QLS-H score between the groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4321405&req=5

fig3: Bar diagram showing the median QLS-H score between the groups.
Mentions: The median (IQR) QOL score in the control group was 153 (143–149). The median (IQR) QoL in the test group before treatment was 45 (36–55.25) which improved to 84.5 (79–100) post treatment (P=0.005, Fig. 3) (Supplementary File 2).

Bottom Line: There was improvement in bone mineral content (P=0.01), bone mineral density (P=0.04), muscle strength (P<0.001), total cholesterol (P=0.003), high-density cholesterol (P<0.001), and QoL - score (P=0.005), and reduction in low-density cholesterol (P=0.003) and triglyceride (P=0.004) after treatment.There was a modest increase in plasminogen activator inhibitor 1 (P=0.002), but it was lower compared with healthy controls and treatment naïve acromegalics (P=0.007).Long-term prospective studies are needed to evaluate the effect of r-hGH therapy in these patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Endocrinology4th Floor, F Block, Post Graduate Institute of Medical Education and Research, Nehru Hospital, Chandigarh 160012, IndiaInternal MedicineCardiologyHematologyHistopathologyGastroenterologyNeurosurgeryPharmacologyRadiodiagnosisPost Graduate Institute of Medical Education and Research, Chandigarh 160012, India pinaki_dutta@hotmail.com.

No MeSH data available.


Related in: MedlinePlus